Aldeyra Therapeutics (ALDX) Common Equity (2013 - 2026)

Aldeyra Therapeutics' Common Equity history runs 14 years deep, the most recent figure standing at $42.2 million for Q1 2026.

• Quarterly Common Equity fell 33.71% year-over-year to $42.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.2 million (down 33.71% YoY) and the FY2025 annual result came in at $44.3 million, down 37.68% from the prior year.
• Common Equity was $42.2 million for Q1 2026 at Aldeyra Therapeutics, down from $44.3 million in the prior quarter.
• Across five years, Common Equity topped out at $190.7 million in Q1 2022 and bottomed at $42.2 million in Q1 2026.
• A 5-year average of $106.5 million and a median of $113.4 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity surged 51.25% — and 2025, when it slumped 43.93%.
• Aldeyra Therapeutics' Common Equity stood at $151.0 million in 2022, then declined by 20.67% to $119.8 million in 2023, then plunged by 40.73% to $71.0 million in 2024, then tumbled by 37.68% to $44.3 million in 2025, then slipped by 4.73% to $42.2 million in 2026.
• Business Quant data shows ALDX's Common Equity at $42.2 million in Q1 2026, $44.3 million in Q4 2025, and $49.2 million in Q3 2025.